Seshu Tyagarajan Sells 7,000 Shares of Candel Therapeutics (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.02, for a total transaction of $70,140.00. Following the completion of the transaction, the chief technology officer directly owned 83,865 shares of the company’s stock, valued at approximately $840,327.30. This trade represents a 7.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Candel Therapeutics Price Performance

Candel Therapeutics stock opened at $9.83 on Friday. The company has a market cap of $720.24 million, a price-to-earnings ratio of -10.03 and a beta of -0.52. The firm’s fifty day moving average is $8.30 and its 200 day moving average is $6.48. The company has a quick ratio of 28.05, a current ratio of 28.05 and a debt-to-equity ratio of 0.34. Candel Therapeutics, Inc. has a 52-week low of $4.35 and a 52-week high of $11.36.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.16. Sell-side analysts forecast that Candel Therapeutics, Inc. will post -0.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on CADL. Canaccord Genuity Group reiterated a “buy” rating and issued a $25.00 price target on shares of Candel Therapeutics in a research report on Friday, March 13th. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Citigroup decreased their price target on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, March 13th. Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Monday, April 20th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Moneta Group Investment Advisors LLC grew its holdings in shares of Candel Therapeutics by 4.9% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company’s stock worth $240,000 after purchasing an additional 2,000 shares during the last quarter. Invesco Ltd. increased its stake in Candel Therapeutics by 29.0% in the 4th quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock worth $85,000 after buying an additional 3,380 shares during the period. Janney Montgomery Scott LLC lifted its holdings in Candel Therapeutics by 12.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock valued at $149,000 after buying an additional 3,400 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Candel Therapeutics by 25.5% during the 4th quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock valued at $110,000 after buying an additional 3,955 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after buying an additional 4,439 shares during the period. Hedge funds and other institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.